PF 4217903

Drug Profile

PF 4217903

Alternative Names: PF-04217903; PF-4217903; PF-4217903-A

Latest Information Update: 04 Mar 2011

Price : $50

At a glance

  • Originator Pfizer
  • Class Amino alcohols; Antineoplastics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 28 Feb 2011 Discontinued - Phase-I for Cancer in USA (PO)
  • 27 Jul 2010 Suspended - Phase-I for Cancer in USA (PO)
  • 19 Mar 2010 Pfizer completes enrolment in its phase I trial for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top